Seres’ ulcerative colitis candidate misses primary endpoint in mid-stage study
Microbiome-based therapeutic failed to improve clinical remission rates among mild-to-moderate ulcerative colitis patients
Read More
Tag: Seres Therapeutics
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
